相关实验视频
Updated: May 29, 2025

08:36
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
7.5K
核糖体RNA生物合成功能性编程瘤相关的巨细胞,以支持乳腺癌的进展
Brandon J Metge1, Li'an Williams1,2, Courtney A Swain1,2
1Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama.
Cancer research
|February 4, 2025
概括
在乳腺癌中,巨细胞中的核糖体生物合成增加推动了瘤生长和免疫逃避. 抑制这一过程将促进瘤的巨细胞转化为抑制瘤的巨细胞,从而提高治疗的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 巨细胞是关键的先天性免疫细胞,但可以被瘤重编程成亲瘤原生表型.
- 与瘤相关的巨细胞 (TAMs) 促进瘤进展和治疗耐药性.
- 在瘤发生过程中,巨细胞的早期重编程并未得到充分理解.
研究的目的:
- 研究核糖体生物合成在瘤微环境中的巨细胞重编程中的作用.
- 确定向核糖体生物合成是否可以改变TAM功能并改善癌症治疗.
主要方法:
- 在前新生和新生乳腺病变中分析巨细胞基因表达.
- 在TAM中评估rRNA合成和核糖体生物发生路径.
- 在乳腺癌模型中使用RNA生物发生抑制剂 (例如BMH-21) 的临床前研究.
- 在抑制rRNA转录时对下游信号通路 (p53,NF-κB) 的研究.
主要成果:
- 前新生体和瘤组织中的巨细胞显示了核糖体生物合成基因的丰富.
- 支持瘤的巨细胞表现出增加的rRNA表达和合成.
- 用BMH-21抑制核糖体生物生成将原瘤巨细胞转化为抑制瘤的表型.
- 向核糖体生物发生导致核细胞应激反应,激活p53和NF-κB通路,导致炎症性巨细胞程序.
- 在临床前模型中,抑制核糖体生物发生增强了新辅助疗法的疗效.
结论:
- 核糖体生物合成是乳腺瘤发生期间前瘤巨细胞重编程的一个早期,持续的事件.
- 向核糖体生物发生是一种新的治疗策略,用于重编程瘤免疫微环境.
- 通过抑制核糖体生物生成来重新激活抑制瘤的巨细胞功能,有望改善癌症治疗结果.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The Nucleolus
8.7K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.7K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K

